E-viri
Recenzirano
-
Ramaekers, Ryan; Tharnish, Mark; Copur, M. Sitki; Wittes, Janet; Casper, Jochen; Schumann-Binarsch, Silke; Köhne, Claus-Henning; Motzer, Robert J; McCann, Lauren; Deen, Keith
The New England journal of medicine, 11/2013, Letnik: 369, Številka: 20Journal Article
To the Editor: Cancer treatments are expensive. The estimation of the total cost can be challenging because of several factors such as efficacy, toxicity, and the costs and duration of supportive care and end-of-life care. Motzer et al. (Aug. 22 issue) 1 report similar efficacy but a favorable safety and quality-of-life profile and less medical resource utilization with pazopanib as compared with sunitinib in first-line therapy for metastatic renal cancer. Since oncology is becoming an increasingly value-based specialty, we wanted to highlight another important aspect of this trial. Pazopanib appears to be favorable not only in terms of safety and quality . . .
